Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1603 in Systemic Lupus Erythematosus
NCT06015230Phase 2Active, not recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Mar 2022
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GR1603 in systemic lupus erythematosus (SLE) (5 arms), sponsored by Zhixiang Jintai. Primary endpoints: Adverse events at 16 weeks and BICLA response at 24 weeks. Started Mar 2022; status: active, not recruiting.
02
Drugs
GR1603
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06015230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015230.